Boots Healthcare Intl.
This article was originally published in The Tan Sheet
Executive Summary
UK retailer/manufacturer to use Bioprogress Technology's XGel soft capsule system under deal announced Nov. 28. Separately, Boots appoints Chuo Bussan Intl. as distributor for Clearasil in Japan, effective Dec. 3. BHI expects to expand Clearasil distribution in 130 countries where Boots products are sold. Line likely will be extended in fiscal 2002 to address greater range of skin conditions, such as psoriasis, firm says. Boots, which purchased Clearasil from P&G last year, recently named Novartis as distributor in U.S. and Canada (1"The Tan Sheet" May 21, In Brief)...
You may also be interested in...
Boots
Novartis Consumer Health named Clearasil distributor in U.S., Canada effective July 2 to strengthen position of skin care brand, UK firm announces. Former Clearasil marketer Procter & Gamble will distribute brand until July 1 and continue to manufacture it in North America until further notice, Boots says. Novartis and Boots will work together to evaluate opportunities for Clearasil, including revamping the line and possibly bringing other Boots OTCs under development in UK to U.S. market, firm says. Boots purchased Clearasil from P&G for $340 mil. (1"The Tan Sheet" Oct. 23, 2000, p. 7)
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.